Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus rhamnosus LDTM 7511
- Development stage
- Preclinical
- Lead developer
- Chong Kun Dang Pharmaceutical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus rhamnosus LDTM 7511 is a probiotic bacterial strain isolated from Korean infant feces, currently under investigation for the treatment of inflammatory bowel disease (IBD). As a live biotherapeutic product, it exhibits anti-inflammatory properties and the ability to modulate gut microbiota. In preclinical studies using dextran sulfate sodium (DSS)-induced colitis murine models, LDTM 7511 demonstrated the capacity to alleviate the release of inflammatory mediators (such as TNF-α, IL-6, and nitric oxide) and normalize bacterial dysbiosis by transitioning the gut microbiome from a diseased state toward a healthy composition. The strain also shows high adherence to intestinal cells and survival in gastrointestinal tract models, suggesting its potential as a therapeutic probiotic for managing intestinal inflammation.
- Other names
- L. rhamnosus LDTM 7511
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))IL-6 (Interleukin 6)NO2- (Nitrite)
Beyond the preview
Go deeper on Lactobacillus rhamnosus LDTM 7511.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus rhamnosus LDTM 7511.